Incidence rates of follicular lymphoma (FL) inexplicably vary markedly between Western and Asian countries. A hallmark of FL is thebcl-2 translocation, characterized by 1 of 2 common breakpoints known as major breakpoint region (MBR) and minor cluster region (mcr). We analyzed previously published data to compare rates ofbcl-2 translocation in FL across geographic regions. Available data from the literature suggest that the incidence ofbcl-2 in healthy persons in the absence of FL may be as high as 50% in Western and Asian populations. However, in FL our results show that the frequency of bcl-2 positivity was significantly higher for US than for Asian populations (P < .0001). This pattern persisted for MBR and mcr subgroups. We conclude that a significant gradient exists in thebcl-2 frequency between these FL populations. We therefore suggest that the relatively low incidence of FL in Asian populations is caused not by a lower frequency of bcl-2 rearrangements in healthy populations but by distinct molecular pathways developing in different geographic regions that nonetheless culminate in FL, which is morphologically similar but molecularly distinct. Studies demonstrating differences in clinical characteristics according to the presence or absence of bcl-2 rearrangements support this concept. Thus we hypothesize that FL may in fact be a heterogeneous malignancy encompassing entities with distinct molecular pathogenesis and potentially distinct clinical manifestations. If these findings were confirmed in prospective studies, it would imply that different etiologic or genetic factors might influence the development of FL across separate regions.

It has been repeatedly observed that there are marked differences in the incidence rates of follicular lymphoma (FL) across geographic regions. Extremely low incidence rates are reported among most Asian countries, and comparatively high rates are reported in North America and Western Europe. Although widely accepted, this observation remains unexplained.

The t(14;18)(q32;q21) translocation, with downstream overexpression of the antiapoptotic bcl-2 protein, is the hallmark of FL. However, this potentially oncogenic mutation has also been identified in a significant proportion of healthy persons. In the absence of clinical disease, the significance of this finding is uncertain but may suggest that the translocation is an early, initiating event, with subsequent cumulative oncogenic alterations necessary to manifest as the clinical entity FL.

Whether there are differences in the incidence of bcl-2translocations in FL across geographic regions has not been thoroughly explored. We have analyzed previously published data to propose that the incidence of the t(14;18) translocation may be significantly lower in patients with FL from Asia than in patients from Western countries. By implication, there may be distinct molecular pathways operating in different geographic regions that nonetheless culminate in FL that is morphologically similar but molecularly distinct. Recently published comparative studies demonstrating differences in clinical characteristics according to the presence or absence ofbcl-2 gene rearrangements support this concept. Based on these observations, we have developed the hypothesis that FL may in fact be a heterogeneous disorder encompassing entities with distinct molecular pathogenesis, in particular bcl-2 germline versus rearranged, and potentially distinct clinical manifestations and natural history.

For many years it has been recognized that FL makes up a relatively small proportion of all cases of non-Hodgkin lymphoma (NHL) diagnosed within most Asian countries (Table1).1-15,17,19 Summary data from many of the larger recent studies reveal that across most nations in this region, only 8% to 12% of consecutive series of newly diagnosed NHL are of follicular histology. Two series with a total of 1756 patients suggest that the proportion may be even lower in Korea—3.8% and 6.2%, respectively.11 12 

Table 1.

Relative frequency of histologic subtypes of NHL

RegionYearNo. casesIncidence by histologic subtypeAll follicular (%)DLCL (%)
FSC (%)FM (%)FLC (%)
Africa/Asia/India        
 Japan10 1983 604 – – – 11.6 – 
 Japan2 1985 294 – – – 10.7 46.2 
 Hong Kong8 1984 267 6.4 3.4 0.4 10.1 18.7 
 Hong Kong3 1998 197 – – – 8.0 39.0 
 Thailand9 1996 1391 1.9 0.9 1.0 3.8 39.9 
 Thailand15 1998 389 2.8 1.8 6.4 11.1 31.3 
 Korea11 1992 290 0.3 1.4 2.1 3.8 58.3 
 Korea12 1998 1466 – – – 6.2 43.7 
 Korea5 1985 298 0.7 2.7 3.4 53.7 
 China7 1987 192 5.2 3.6 5.2 14.0 24.5 
 Philippines4 1986 262 4.2 3.8 8.0 29.7 
 India6 1985 238 5.9 2.5 0.4 8.8 39.1 
 India13 1985 1050 – – – 10.0 – 
 Taiwan14 1991 636 2.9 1.8 1.8 6.3 54.9 
 Pakistan17 1992 495 – – – 8.1 41.0 
 Gabon19 1991 72 1.5 1.5 35.8 
North America/Europe/South Africa        
 United States3 1998 200 – – – 32 28 
 Canada3 1998 200 – – – 31 31 
 South Africa3 1998 188 – – – 33 31 
 Britain3 1998 119 – – – 28 29 
 Germany3 1998 203 – – – 18 30 
 France3 1998 192 – – – 17 39 
 Italy3 1998 79 – – – 11 45 
 United States1 1982 1153 22.5 7.7 3.8 34.0 27.6 
RegionYearNo. casesIncidence by histologic subtypeAll follicular (%)DLCL (%)
FSC (%)FM (%)FLC (%)
Africa/Asia/India        
 Japan10 1983 604 – – – 11.6 – 
 Japan2 1985 294 – – – 10.7 46.2 
 Hong Kong8 1984 267 6.4 3.4 0.4 10.1 18.7 
 Hong Kong3 1998 197 – – – 8.0 39.0 
 Thailand9 1996 1391 1.9 0.9 1.0 3.8 39.9 
 Thailand15 1998 389 2.8 1.8 6.4 11.1 31.3 
 Korea11 1992 290 0.3 1.4 2.1 3.8 58.3 
 Korea12 1998 1466 – – – 6.2 43.7 
 Korea5 1985 298 0.7 2.7 3.4 53.7 
 China7 1987 192 5.2 3.6 5.2 14.0 24.5 
 Philippines4 1986 262 4.2 3.8 8.0 29.7 
 India6 1985 238 5.9 2.5 0.4 8.8 39.1 
 India13 1985 1050 – – – 10.0 – 
 Taiwan14 1991 636 2.9 1.8 1.8 6.3 54.9 
 Pakistan17 1992 495 – – – 8.1 41.0 
 Gabon19 1991 72 1.5 1.5 35.8 
North America/Europe/South Africa        
 United States3 1998 200 – – – 32 28 
 Canada3 1998 200 – – – 31 31 
 South Africa3 1998 188 – – – 33 31 
 Britain3 1998 119 – – – 28 29 
 Germany3 1998 203 – – – 18 30 
 France3 1998 192 – – – 17 39 
 Italy3 1998 79 – – – 11 45 
 United States1 1982 1153 22.5 7.7 3.8 34.0 27.6 

FSC indicates follicular small-cleaved cell; FM, follicular mixed; FLC, follicular large cell; and DLCL, diffuse large-cell lymphoma.

These figures contrast dramatically with the relative proportion of 20% to 33% reported for most industrialized North American and Western European countries. In this context, it is interesting to note that data reported from Cape Town, South Africa conform to the pattern of the Western European centers, with 33% of all lymphomas having follicular histology. Notably, northern Italy appears to provide an exception to this observation, with only 11% of all lymphomas reported as of follicular histology.3 

Although the available data in developing nations outside Asia are less complete, the relative frequency of FL is similar to that of the Asian countries, with proportions of 16.7% reported in Oman,168.1% in Pakistan,17 13.3% in Nigeria,18 and 1.5% in Gabon, equatorial Africa.19 These similar frequencies occur despite marked variation in the ethnic background and geographic localization of these regions, consistent with a dominant effect for environmental rather than genetic influences. This is also consistent with the data derived from Asian emigrants to the United States and their descendants,20 in which emigrants to the United States appeared to maintain the disease risk of their country of birth and early development, whereas the incidence among the children born in the United States approached that of US-born whites.

Although the above figures allow comparisons of therelative proportion of various lymphoma types between countries, they do not provide data on the absoluteincidence rates. Unfortunately, most of the available population-based incidence figures do not include specific histologic subtyping. Much of the following discussion therefore relies on application of the above relative proportions observed in the above hospital-based series to population-based overall incidence figures and thus assumes that the relative distribution of histologic types is representative of that seen in the country as a whole. An important factor, which will have an impact on these international comparisons, is the age structure of the populations under scrutiny. However, even allowing for an extreme effect of population demographics such as that presented by Hakulinen for Quito, Ecuador, where the median age of the population is just 20 years, such adjustment to “world standard” population resulted in an increase in less than 50% in the crude incidence rates.21 The application of such extreme adjustment factors to the presented data for most Asian countries would not significantly alter the conclusions presented herein.

Reliable population-based data on specific incidence rates for FL are available for the United States. The most recent direct data available for histologic subtypes is from SEER registry for 1986 to 1988,22 in which the annual incidence rate (per 100 000 population) for follicular small-cleaved cell (FSC) lymphoma was 1.3, follicular mixed (FM) lymphoma was 0.7, and follicular large (FLC) lymphoma was 0.4. The cumulative annual incidence rate for all forms of FL steadily increased from 1978 to 1995: it was 2.0 for 1978 to 1981, 2.3 for 1982 to 1985, 2.4 for 1986 to 1988, and 2.6 for the overall period from 1978 to 1995. Within the United States, distinct from the increased incidence related to HIV lymphomas, the overall incidence of NHL has been increasing by approximately 3.4% per year, a trend that is apparent worldwide.23 (The rate of increase, however, might have slowed in the last decade, as evidenced by a 0.4% annual increase in US statistics from 1991 to 1998.24) Aggressive histologic types have a higher rate of increase, such that the overall rate of increase for FL is less at approximately 2% per year.22,25,26 An updated SEER registry analysis to 1995 suggests the increase in FL incidence is attributed mainly to an increase in incidence of FM and FLC subtypes.27 With the recent introduction of the World Health Organization classification system,28 the criteria for the cytologic subclassification of FL will be changed to that initially proposed by Mann and Berard,29 which yields a higher proportion of FL subtypes than previously used cytologic classification systems.30 31 

Applying population-based overall incidence figures for NHL to the estimated proportion of follicular NHL from the available studies (if more than one study from a given country was available, the mean figure was used), yields estimated annual incidence rates for FL in Asian countries in the range of 0.15 to 0.38 per 100 000 population per year (Table 2).18,22,25 32-34This is clearly much lower than the rate of 1.3 to 3.0 per 100 000 population per year seen in the industrialized Western European and North American countries. Thus it is clear that the relative infrequency of FL reported from Asian countries results from a truly low incidence rate; averaging less than 10% of that seen in North America and most industrialized Western European nations.

Table 2.

Incidence rates for overall NHL and follicular histologic types by country

Country-regionOverall NHL rateDerived incidence
follicular NHL
Japan-Miyagi22 2.5* 0.28 
Japan-Osaka22 3.4* 0.38 
India-Bombay22 2.3* 0.20 
Thailand-Khon Kaen34 3.1* 0.23 
Thailand32 2.1* 0.15 
China-Qidong34 2.4* 0.34 
Philippines32 3.5* 0.28 
Nigeria-Jos18 9.1 1.20 
Canada-Quebec34 11.1* 3.44 
Canada-British Columbia22 7.8* 2.42 
Germany-Hamburg33 2.9* 0.52 
United Kingdom25 12.2 3.42 
France25 13.2 2.24 
Italy32 6.53* 0.72  
United States22 13.9* 2.4 
Country-regionOverall NHL rateDerived incidence
follicular NHL
Japan-Miyagi22 2.5* 0.28 
Japan-Osaka22 3.4* 0.38 
India-Bombay22 2.3* 0.20 
Thailand-Khon Kaen34 3.1* 0.23 
Thailand32 2.1* 0.15 
China-Qidong34 2.4* 0.34 
Philippines32 3.5* 0.28 
Nigeria-Jos18 9.1 1.20 
Canada-Quebec34 11.1* 3.44 
Canada-British Columbia22 7.8* 2.42 
Germany-Hamburg33 2.9* 0.52 
United Kingdom25 12.2 3.42 
France25 13.2 2.24 
Italy32 6.53* 0.72  
United States22 13.9* 2.4 
*

Adjusted to “world standard” population.

Adjusted to similar age-standardized population. See reference for details.

Not population-adjusted.

Bcl-2 oncogene structure and function

Many excellent thorough reviews of this area have been published in recent years.35-37 In summary, bcl-2 is the archetypal member of a growing family of apoptosis-regulating genes. More than 15 members of this family are known, and these fall into either apoptotic death-inducing or death-inhibitory classes. The ultimate cellular response to a potentially proapoptotic extracellular signal is determined by the ratio of antiapoptotic to proapoptotic bcl-2 family proteins. This dynamic balance has been termed the apoptotic rheostat, and it is mediated by competitive dimerization between selective pairs of antagonists and agonists.36 37In this context, clearly any genetic changes that alter the level of expression of one or another of this dynamically balanced system will profoundly influence the likelihood of a cell undergoing programmed cell death in response to a given physiologic stimulus.

Bcl-2 gene rearrangement in FL

The most common nonrandom chromosomal translocation identified to date in FL (as reported in the United States) is the balanced translocation between the immunoglobulin heavy-chain gene on chromosome 18 and the bcl-2 gene on chromosome 14. The resultant t(14;18)(q32;q21) leads to constitutive overexpression of a structurally intact and functional bcl-2 protein38-40 and is the hallmark of FL. Functionally, this results in a prolongation of cell survival and expansion of follicular lymphoid tissue. The survival advantage that bcl-2 mutations confer on lymphocytes may predispose these cells to accumulation of further DNA damage.41 42 

Most of the observed t(14;18) translocations have breakpoints clustered in 1 of 2 sites on chromosome 18. The major breakpoint region (MBR), which is involved in approximately 70% of observed translocations, is in the untranslated region 3′ of the last exon of the bcl-2gene. The minor cluster region (mcr), which accounts for 10% to 15% of observed translocations, is 30 kb downstream of the bcl-2gene. The tight physical clustering of breakpoints within the 2 defined regions of the bcl-2 gene facilitates effective screening for the presence of the t(14;18) translocation by polymerase chain reaction (PCR) using paired primers for an immunoglobulin heavy chain JH consensus sequence together with either MBR or mcr sequence, the methods for which are detailed elsewhere.43Additional but less common breakpoint regions lying between the MBR and mcr have also been identified but constitute a trivial proportion of detected translocations.44 45 

In the remaining 15% to 20% of patients with FL, the bcl-2gene appears to be physically intact using all available methods.46 Despite this apparent germline configuration, overexpression of the bcl-2 protein evident in 90% of these cases.47-49 Thus, through known genetic translocations, as yet unidentified structural chromosomal changes, or alternative mechanisms, as many as 98% of all cases of FSC (grade 1) lymphoma are associated with bcl-2 protein overexpression.50 The frequency of overexpression in histologic grades 2 and 3 (FM and FLC) FL is slightly lower, in the 75% to 85% range.51 These observations provide overwhelming support for the hypothesis thatbcl-2 overexpression is critically involved in the pathogenesis of FL.

Based on the above data clearly linking bcl-2 gene rearrangements with FL, many investigators had previously suggested that the detection of such a translocation was diagnostic of NHL and most frequently was associated with follicular disease. The first study demonstrating conclusively that clonal bcl-2 rearrangements could be detected in the absence of clinically manifest FL appeared in 1991, by Limpens et al52 at the University of Leiden. Using sensitive nested PCR capable of detecting one clonal cell in 200 000, they demonstrated bcl-2–JH gene rearrangements in 9 (56%) of 16 lymph nodes with follicular hyperplasia and in 4 (50%) of 8 of tonsils with follicular hyperplasia. Since that time additional studies have confirmed this initially unexpected result (Table3).52-65 Excluding the study by Fuscoe et al,56 which used a significantly more sensitive technique (able to detect one clonal cell in 10 000 000), and the study by Ohshima,60 which used a low-sensitivity, single-step methodology, the overall positivity rates for the various tissues tested are bone marrow, 14% (11/78)52,61; spleen, 35% (11/31)59; tonsils, 40% (12/30)52,53; peripheral blood, 28.7% (473/1646)54,55,57-59,61,62-65; and follicular hyperplasia nodes, 58% (11/19)52 53(Figure 1).

Table 3.

Overview of studies of bcl-2 rearrangement in persons without FL

Author/regionPCR method (no. cycles)Amount DNATissue samplesMedian age, y (range)Percentage positiveFrequency (per 106 cells)Comments
Limpens et al/Europe52 Nested (50) 1 μg Follicular hyperplasia 33 (7-78) 56 (9/16) 1-100 —  
 —  —  Reactive tonsils 4-8 50 (4/8) 1-1000 —  
 —  —  Reactive nodes NR 0 (0/19) NR —  
 —  —  Normal marrow NR 0 (0/30) NR —  
Aster et al/United States53 Seminested (60) 2 μg Tonsils 6.5 (2-32) 25 (3/12) 0.4-2.4 —  
 —  —  Follicular hyperplasia 34 (25-64) 67 (2/3) 0.5-4.6 —  
Aster et al/Japan53 —  —  Tonsils 6 (3-40) 50 (5/10) 0.3-60.2 —  
Ohshima et al/Japan60 Single-step (NR) NR Reactive nodes NR 11 (2/18) NR —  
Liu et al/United States59 Nested (60) 2 μg Sorted PB B cells 50 (0-75) 55 (29/53) 0.8-32 Frequency ∝ age 
 —  —  Autopsy spleen 50 (0-85) 35 (11/31) 2.7-853 Liver + 1/10; other tissues negative  
Bell et al/United States54 Nested (60) 2 μg Sorted PB B-cells Younger than 52 48 (59/122) NR ↑ In smokers, no association with age  
Limpens et al/Europe58 Seminested (56) 1 μg Sorted PB B-cells NR 67 (6/9) ≈ 10 —  
Ji et al/United States57 Seminested (46) ≥ 7 μg Normal PB 6-60 and older 63 (79/125) 0.2-180 Higher with age, M > F 
Dolken et al/Europe55 Nested (60) 0.01-1 μg PB mononuclear cells 38 (23-90) 46 (26/57) 1-100 No association with age 
Fuscoe et al/United States56 Nested (60) 2.5 μg PB lymphocytes 27 (17-48) 88 (30/34) 0.08-960 No association with age. M = F  
Rauzy et al/Europe61 Seminested (70) ∼ 0.5 μg Marrow 68 (1-89) 23 (11/48) NR Association with smoking 
 —  —  PB 70 (1-100) 44 (60/137) NR No association with age, sex, or smoking  
Delage et al/Canada63 Nested (25 + 35) 1 μg PB mononuclear cells 41 (38-64) 100 (6/6) 1 K-10 K Multiple MBR, mcr in 5/6  
Summers et al/United Kingdom62 RT-PCR (40) 1.5 μg PB 42 (21-69) 23 (112/481) 104 No association with age  
Yasukawa et al65 Nested (30) 10 μg PB mononuclear cells NR 44 (17/39) NR German population  
 —  —  PB mononuclear cells NR 15 (6/39) NR Japanese population  
Paltiel et al/Israel64 Nested (NR) NR Sorted PB B cells NR 6.9 (24/346) NR No association with age, sex, smoking, or rural residence 
Author/regionPCR method (no. cycles)Amount DNATissue samplesMedian age, y (range)Percentage positiveFrequency (per 106 cells)Comments
Limpens et al/Europe52 Nested (50) 1 μg Follicular hyperplasia 33 (7-78) 56 (9/16) 1-100 —  
 —  —  Reactive tonsils 4-8 50 (4/8) 1-1000 —  
 —  —  Reactive nodes NR 0 (0/19) NR —  
 —  —  Normal marrow NR 0 (0/30) NR —  
Aster et al/United States53 Seminested (60) 2 μg Tonsils 6.5 (2-32) 25 (3/12) 0.4-2.4 —  
 —  —  Follicular hyperplasia 34 (25-64) 67 (2/3) 0.5-4.6 —  
Aster et al/Japan53 —  —  Tonsils 6 (3-40) 50 (5/10) 0.3-60.2 —  
Ohshima et al/Japan60 Single-step (NR) NR Reactive nodes NR 11 (2/18) NR —  
Liu et al/United States59 Nested (60) 2 μg Sorted PB B cells 50 (0-75) 55 (29/53) 0.8-32 Frequency ∝ age 
 —  —  Autopsy spleen 50 (0-85) 35 (11/31) 2.7-853 Liver + 1/10; other tissues negative  
Bell et al/United States54 Nested (60) 2 μg Sorted PB B-cells Younger than 52 48 (59/122) NR ↑ In smokers, no association with age  
Limpens et al/Europe58 Seminested (56) 1 μg Sorted PB B-cells NR 67 (6/9) ≈ 10 —  
Ji et al/United States57 Seminested (46) ≥ 7 μg Normal PB 6-60 and older 63 (79/125) 0.2-180 Higher with age, M > F 
Dolken et al/Europe55 Nested (60) 0.01-1 μg PB mononuclear cells 38 (23-90) 46 (26/57) 1-100 No association with age 
Fuscoe et al/United States56 Nested (60) 2.5 μg PB lymphocytes 27 (17-48) 88 (30/34) 0.08-960 No association with age. M = F  
Rauzy et al/Europe61 Seminested (70) ∼ 0.5 μg Marrow 68 (1-89) 23 (11/48) NR Association with smoking 
 —  —  PB 70 (1-100) 44 (60/137) NR No association with age, sex, or smoking  
Delage et al/Canada63 Nested (25 + 35) 1 μg PB mononuclear cells 41 (38-64) 100 (6/6) 1 K-10 K Multiple MBR, mcr in 5/6  
Summers et al/United Kingdom62 RT-PCR (40) 1.5 μg PB 42 (21-69) 23 (112/481) 104 No association with age  
Yasukawa et al65 Nested (30) 10 μg PB mononuclear cells NR 44 (17/39) NR German population  
 —  —  PB mononuclear cells NR 15 (6/39) NR Japanese population  
Paltiel et al/Israel64 Nested (NR) NR Sorted PB B cells NR 6.9 (24/346) NR No association with age, sex, smoking, or rural residence 

NR indicates not recorded; PB, peripheral blood.

Fig. 1.

Summary of literature results for percentage of samples from various tissues positive for bcl-2 gene rearrangements from persons without evidence of lymphoma.

Data are presented as percentages and 95% CI, with total number of samples examined indicated above each tissue. See text for details and references.

Fig. 1.

Summary of literature results for percentage of samples from various tissues positive for bcl-2 gene rearrangements from persons without evidence of lymphoma.

Data are presented as percentages and 95% CI, with total number of samples examined indicated above each tissue. See text for details and references.

Close modal

Similar results have been obtained using fluorescence in situ hybridization in 4 of 32 lymph nodes involved by nonneoplastic lymphoproliferative disorders, with estimates of the frequency ofbcl-2–rearranged cells of 2% to 5%.66 In comparison, using PCR, the frequency of such cells containing thebcl-2 translocation appears to be approximately 1 in 106 to 1 in 104 cells in most of these studies, but there have been some suggestions that the rate of positivity within the whole study population and the frequency of clonal cells within a single person may be associated with other known risk factors for FL, consistent with the premise that cells carrying abcl-2–JH rearrangement in healthy persons may be precursor cells that subsequently give rise to clinical disease.

The next issue to be considered is whether these sporadicbcl-2 rearrangements detected in healthy persons have a similar clustering of breakpoints, as is known to occur in patients with FL. At this time, such a comparison is limited to examination of the approximately 500–base pair (bp) MBR region, because studies in healthy persons have been limited to this region. Even with this caveat, it is still of interest to compare the distribution of breakpoint sites within the MBR region in patients with FL and in healthy persons. Such an analysis requires not just detection of abcl-2 gene rearrangement but the generation of adequate PCR product for full sequencing. This has been achieved and reported for 126 breakpoint sites in persons without FL,53,55,56,58,61-63 and it is compared with the breakpoint sites from 71 patients with FL.53,67-75Although there are minor discrepancies, such as a slight excess of breakpoints clustered in the area of bp 3165 among healthy persons (20% vs 7% NHL) and a lower frequency of breakpoints in the area of bp 3105 among healthy persons (12% vs 23% NHL), clear clustering in the regions of bp 3055, 3105, 3115, and 3165 are evident (Figure 2). This is consistent with the premise that the translocations found in healthy persons are molecularly indistinguishable from those found in patients with FL and may act as precursor lesions for the later development of FL. This would suggest that the t(4;18)-bearing clonal cells are stable and persistent within the patient over a significant period of time, as observed by Liu et al.59 Specific t(14;18)-bearing clones from peripheral blood lymphocytes of 2 healthy persons persisted over a 5-month period. Further, they found no increase in the number of individual clonal sequences with age. Prospective longitudinal follow-up of healthy persons who harbor a bcl-2translocation without FL and of t(14;18)-bearing healthy persons who acquire FL are clearly needed to substantiate this issue.

Fig. 2.

Comparison of breakpoint sites within MBR forbcl-2 gene rearrangements from healthy persons and patients with FL.

See text for details and references.

Fig. 2.

Comparison of breakpoint sites within MBR forbcl-2 gene rearrangements from healthy persons and patients with FL.

See text for details and references.

Close modal

On the basis of the above premise, it is of interest to examine the putative causal factors in the development of bcl-2rearrangements in healthy persons and in FL patients. Although a large number of epidemiologic factors have been repeatedly studied in FL, the limited data available on bcl-2 incidence in persons without FL restricts our present discussion to an abbreviated list of these factors, including age, sex, and smoking history.34 

Age

As with other histologic NHL subtypes, FL incidence increases steadily with age. The relationship between age and frequency ofbcl-2–rearranged cells in healthy populations has been examined in a number of the larger studies. However, it is important to note that all of these have been merely correlative. There are no studies of longitudinal assessment over significant periods of time explore any changes over time. Liu et al59 first observed a higher frequency of bcl-2 positivity in the spleens of people 30 years of age and older (11/19 or 58%) compared with those younger than 30 (0/12 or 0%; P = .001) and further noted a direct correlation between age and the frequency of t(14;18)-containing cells in peripheral blood lymphocyte samples (r = 0.37; P = .0067) and spleens (r = 0.59; P = .0005). Given that there was no change in the number of individual clonal sequences isolated from any given person with increasing age, this was consistent with the progressive accumulation of cells from a single clone rather than the acquisition of additional separate clones with increasing age.

A later study by the same group of investigators54 looking at a larger group of 122 healthy volunteers (all younger than 52) was unable to show any association of bcl-2 frequency with age, but this might have been because of the lack of truly elderly patients within the cohort given that their earlier study found the most significant increase in rates and frequencies of bcl-2rearrangements among those older than 60. Four subsequent studies have also explored this issue55-57,61; only the large study of Ji et al57 found a clear association (r = 0.37; P < .0001). Two of the negative studies were limited in size and power, with 57 and 34 patients only,55,56 but the large study of 137 patients by Rauzy et al61 also failed to find any association. In summary, one possible explanation for these observations is that though there may be no clear association between age and the actual rate of positivity forbcl-2–rearranged cells in the peripheral blood of healthy persons (using assays with sensitivities in the range of 10−5 to 10−6), there appears to be an association between the frequency of such cells with increasing age, at least in persons older than 60. This explanation would also be consistent with the observation that using assays of greater sensitivity (less than 10−7), almost all persons have detectable clonally rearranged cells (88%) regardless of age.56 

Sex

There is a uniform sex imbalance in the frequency of FL, with males predominating in all population-based studies. Similarly, in 2 of the 5 studies examining the relationship between sex andbcl-2 rearrangements in healthy persons, males were more frequently positive.54,57 However, there is no intrinsic explanation for this sex imbalance, and it may simply be a surrogate marker for a higher likelihood of exposure to other causative agents, such as tobacco, pesticides, or other environmental factors; however, the one study specifically examining likely pesticide exposure (as indicated by rural residence) found no increased risk forbcl-2 rearrangement.64 

Smoking

At least 4 relatively large studies consistently report trends for higher rates of NHL among smokers, with relative risk (RR) values of 1.5,76 1.4,77 2.1,78 and 1.9 (but restricted to women).79 Thus it is highly likely that smoking contributes to NHL risk, but the strength of this association is relatively weak. Some provocative preliminary data suggest that smoking may specifically increase the risk for FL. This evidence is direct and indirect. Herrinton and Friedman80 specifically examined the relationship between smoking habits and histologic subtypes of NHL in the Kaiser Permanente cohort of 252 836 people in California; though smoking was not associated with an increased risk for NHL generally (RR, 1.1; 95% confidence interval [CI], 0.9-1.3), there was a statistically significant increase in the risk for FL among former smokers (RR, 1.9) and current smokers (RR, 1.4). Indirect supporting evidence was provided by Nelson et al,81 who specifically examined risk factors for intermediate-grade NHL and found no association with smoking habits, consistent with the established influence being restricted to other histologic types. Conversely, Brown et al77 found that the RR was greatest for histologically aggressive subtypes (2.3 vs 1.4 overall RR).

In healthy populations the Bell study specifically addressed smoking, finding strong associations in multivariate analysis between indices of tobacco use and the frequency of bcl-2–rearranged cells, whether this was measured by total pack-years (P = .0004), cigarettes smoked per day (P = .008), or total years of smoking (P = .001).54 Given the epidemiologic link between FL and smoking discussed above, the large number of patients studied, and the thorough smoking history data obtained, this study strongly suggests a causative link between a substance contained within tobacco smoke and the generation of bcl-2–IgH rearrangements within peripheral blood lymphocytes. The Rauzy et al61 study also found a greater cumulative cigarette exposure among people with bcl-2 positivity in bone marrow samples (17.5 vs 4.0 pack-years; P < .01461), though a comparison between smokers and nonsmokers in the same study failed to show a difference. Such an association has not been universal, however.64 

To summarize the impact of putative epidemiologic factors, there is consistency in the observed association of increasing age, male sex, and smoking history among t(14;18)-bearing healthy persons and patients with FL.

If these sporadic bcl-2 translocations found in healthy persons truly are the precursor lesions for later development of FL, their frequency may vary in geographic regions with different incidence patterns for FL. Unfortunately, few data are available on the frequency of such gene rearrangements in Asian populations. In the Aster study,53 10 excised tonsils from Japanese persons were examined, and 5 (50%) harbored clonally rearranged cells. By comparison, a positivity rate of 33% (5/15) was reported among similarly examined tonsils and follicular hyperplasia lymph nodes from Americans. In a separate report comparing peripheral bloodbcl-2 status between healthy Japanese and German subjects, only 16% (39/241) of the Japanese study population carried the translocation.65 However, this percentage ofbcl-2 positivity is nonetheless relatively high for the incidence of FL in Japan. Although the number of studies is small, derive from a single Asian ethic group, and do not include mcr, these data do suggest that sporadic bcl-2 gene rearrangements are not rare events among Asians.

More data are available on the relative rates of bcl-2rearrangement positivity among European populations, who have an intermediate incidence of FL, and Americans with a high rate. Restricting this analysis to those studies using PCR methods of similar sensitivity,54,55,57-59,61 65 the cumulative incidence of detectable bcl-2 gene rearrangements in the peripheral blood of Europeans is 47% (131/278), and among Americans it is 53% (162/308) (P = .21). Allowing for differences in methodological sensitivity between groups and the inability to match for the age of subjects, sex distribution, and possible confounding factors such as smoking habits, there are clearly no marked differences evident in the rate of detection of bcl-2 rearrangements.

If we accept that the reported bcl-2 rearrangements among healthy persons are the precursor lesions for the subsequent development of FL, this similarity in the frequency of bcl-2rearrangements, despite markedly lower incidence of FL, strongly suggests that additional molecular events are required subsequent to the acquisition of a clonal bcl-2–IgH rearrangement before clinically evident FL can develop. In addition, it appears that such later events, rather than the bcl-2 rearrangements, are rate-limiting for the development of clinical disease. The nature of these putative additional events remains speculative, and the likely causative factors are unknown. Factors that influence the development of subsequent molecular events may in fact vary between geographic regions. Hence, these geographic variations might explain the different incidences of FL.

As we have demonstrated, there is marked geographic variation in the incidence of FL. We have also suggested that the background rate ofbcl-2 gene rearrangement in the absence of disease is inadequate to explain the magnitude of observed differences in the incidence of FL between geographic regions. Does FL from different regions share similar underlying molecular defects, or is there evidence of distinct molecular pathogenesis?

This specific issue was addressed in the recent study by Segel et al82 of Jerusalem. They performed PCR for MBRbcl-2 gene rearrangement on FL specimens from 36 patients, finding 61% positive, and reviewed all published studies of the frequency of bcl-2 gene rearrangement in FL up to 1995. To minimize the influence of variability in assay sensitivity between studies, we have limited the following discussion to the comparison of PCR results in which MBR and mcr loci were examined, and we have also included later studies, in particular the recent large series from the MD Anderson Cancer Center in Texas.83 Although there is likely to be some level of variability in the sensitivity of the assays used between laboratories, this will have little impact on the rates of positivity among primary diagnostic tissue samples because such nodes are usually heavily infiltrated by the malignant cells. Conversely, whether fresh or archival material is used as the source of DNA will have a minor influence. As clearly shown by the comparative study of Liu et al,84 the rate of positivity for bcl-2rearrangements will be approximately 10% lower when applied to archival material because of degradation of the DNA. Because PCR products from the mcr breakpoints on average are approximately 3 times larger than MBR breakpoint products, there will be a proportionately greater loss of sensitivity for rearrangements at the mcr locus. Unfortunately, the use of frozen versus archival material was variable between studies and indeed between reports from different geographic regions, with more frequent use of fresh tissue among the North American series. Allowance for such methodological variations may increase the true positivity rate for the samples from Asian patients by 5% to 10% and from European patients by approximately 5%. However, the series of Loke et al,85 which found a 60% rate of bcl-2 rearrangements among Hong Kong Chinese patients, did use frozen tissue in all cases.

Overall, even allowing for such methodological differences, these results (Table 4) demonstrate a significant gradient in the frequency of bcl-2 gene rearrangements from a relatively low rate of 48% to 55% among Asian and European studies to approximately 80% among the series reported from the United States (95% CI, 74%-83%;P < .0001).47,66 83-94 These differences were evident among MBR rearrangements (45%-50% vs 65%, respectively; P = .001 and mcr rearrangements (4%-5% vs 13%, respectively; P = .003).

Table 4.

Frequency of bcl-2 gene rearrangement in follicular NHL from different geographic regions

Region and authorNo. patients
evaluable
MBR+ (%)mcr+ (%)Total bcl-2+ (%)
Asia     
 Mitani et al92 304-150 12  (40) 1  (3) 13  (43)  
 Loke et al4-15185 16 8  (50) 1  (6) 9  (56) 
  Subtotal (percentage; 95% CI) 46 20  (43; 29-59) 2  (4; 0.5-15) 22  (48; 33-63) 
Europe     
 Benitez et al86 3  (60) 0  (0) 3  (60) 
 Pezzella et al93 51 18  (35) 3  (6) 21  (41)  
 Lee et al91 20 7  (35) 1  (5) 8  (40)  
 Lambrechts et al90 21 12  (57) 1  (5) 13  (62) 
 Poetsch et al66 28 18  (64) 0  (0) 18  (64)  
 Séité et al47 64 30  (47) 8  (13) 38  (59) 
 Johnson et al89 50 30  (60) 0  (0) 30  (60)  
  Subtotal (percentage; 95% CI) 239 118  (49; 43-56) 13  (5; 3-9) 131  (55; 48-61)  
United States     
 Zelenetz et al94 40 22  (55) 6  (15) 28  (70)  
 Liu et al84 48 24  (50) 5  (10) 29  (60) 
 Gribben et al87 88 56  (64) 18  (20) 74  (84)  
 Gulley et al88 4  (50) 1  (12) 5  (62)  
 Lopez-Guillermo et al83 139 105  (70) 13  (9) 118  (79) 
  Subtotal (percentage; 95% CI) 323 211  (65; 60-70) 43  (13; 10-17) 254  (79; 74-83) 
Region and authorNo. patients
evaluable
MBR+ (%)mcr+ (%)Total bcl-2+ (%)
Asia     
 Mitani et al92 304-150 12  (40) 1  (3) 13  (43)  
 Loke et al4-15185 16 8  (50) 1  (6) 9  (56) 
  Subtotal (percentage; 95% CI) 46 20  (43; 29-59) 2  (4; 0.5-15) 22  (48; 33-63) 
Europe     
 Benitez et al86 3  (60) 0  (0) 3  (60) 
 Pezzella et al93 51 18  (35) 3  (6) 21  (41)  
 Lee et al91 20 7  (35) 1  (5) 8  (40)  
 Lambrechts et al90 21 12  (57) 1  (5) 13  (62) 
 Poetsch et al66 28 18  (64) 0  (0) 18  (64)  
 Séité et al47 64 30  (47) 8  (13) 38  (59) 
 Johnson et al89 50 30  (60) 0  (0) 30  (60)  
  Subtotal (percentage; 95% CI) 239 118  (49; 43-56) 13  (5; 3-9) 131  (55; 48-61)  
United States     
 Zelenetz et al94 40 22  (55) 6  (15) 28  (70)  
 Liu et al84 48 24  (50) 5  (10) 29  (60) 
 Gribben et al87 88 56  (64) 18  (20) 74  (84)  
 Gulley et al88 4  (50) 1  (12) 5  (62)  
 Lopez-Guillermo et al83 139 105  (70) 13  (9) 118  (79) 
  Subtotal (percentage; 95% CI) 323 211  (65; 60-70) 43  (13; 10-17) 254  (79; 74-83) 
F4-150

Restricted to FSC and FM; FLC not included.

F4-151

Analysis by Southern blotting only performed.

Ideally, it is preferable to have results from simultaneously processed fresh samples representing each geographic region for analysis in a single laboratory, but in the absence of such data, the above comparisons must suffice. Notwithstanding the shortcomings of the limited data set available in published literature, there appears to be a discrepancy in the frequency of bcl-2 gene rearrangements in FL across geographic regions. If these apparent geographic variations are confirmed in larger epidemiologic studies, it suggests the existence of separate pathogenetic processes, each of which culminates in morphologically similar, but molecularly distinct, FL. This is analogous to the recent demonstration that gastric marginal zone B-cell lymphomas appear to consist of 2 pathogenetically discrete entities (with or without t(11;18)) that have different natural histories.95 

Although this 2-pathway model remains speculative, previously published results of clinical characteristics and treatment outcomes of patients with FL support this hypothesis (Tables5, 6). For instance, Lopez-Guillermo et al83 found that patients with germline bcl-2 status were older at diagnosis, had more advanced-stage disease, and had higher serum levels of LDH and β2-microglobulin, all suggestive of a higher disease burden, than patients with rearranged bcl-2. A relationship between age and germline bcl-2 gene status was also reported in 2 smaller studies.89 96 More provocatively, though patients with germline bcl-2 had a lower CR rate with therapy, the pattern of relapse was more suggestive of aggressive NHL, with approximately 40% of patients experiencing relapse within 3 years but no relapses observed beyond 3 years. This pattern of relapse appeared distinct from the slow but relentless relapse rate observed for most series of patients with advanced FL.

Table 5.

Clinical characteristics of bcl-2 positive versus germline cases of FL in published series

CountryNo. FL patients
(positive forbcl-2)
Method of
analysis
Clinical characteristics, bcl-2 positive versus germline cases
AgeSexStageHistologyLDHβ2MBMEnodal
United States113 30  (23) CG NS NS NS NS NS —  —  —  
United States99 20  (13) CG NS NS NS —  —  —  —  NS 
Denmark93 70  (39) PCR NS NS NS NS —  —  NS —  
Sweden89 102  (42) PCR Younger5-150 —  NS —  NS —  NS NS 
United States83 247  (202) PCR Younger5-152 —  Earlier5-151 NS Lower5-152 Lower5-151 —  NS 
Canada97 212  (164) CG NS NS Higher5-150 Lower Gr5-150 NS —  Increase5-150 Lower5-151 
United States96 46  (22) PCR Younger5-151 —  Earlier5-151 —  —  —  Decrease5-151 — 
CountryNo. FL patients
(positive forbcl-2)
Method of
analysis
Clinical characteristics, bcl-2 positive versus germline cases
AgeSexStageHistologyLDHβ2MBMEnodal
United States113 30  (23) CG NS NS NS NS NS —  —  —  
United States99 20  (13) CG NS NS NS —  —  —  —  NS 
Denmark93 70  (39) PCR NS NS NS NS —  —  NS —  
Sweden89 102  (42) PCR Younger5-150 —  NS —  NS —  NS NS 
United States83 247  (202) PCR Younger5-152 —  Earlier5-151 NS Lower5-152 Lower5-151 —  NS 
Canada97 212  (164) CG NS NS Higher5-150 Lower Gr5-150 NS —  Increase5-150 Lower5-151 
United States96 46  (22) PCR Younger5-151 —  Earlier5-151 —  —  —  Decrease5-151 — 

β2M indicates beta2 microglobulin; BM, bone marrow; Enodal, extranodal; CG, cytogenetics; NS, not significant.

F5-150

P < .01.

F5-151

P = .01-.05.

F5-152

P > .05.

Table 6.

Outcome measures of bcl-2 positive versus germline FL and impact of additional genetic alterations

CountryOutcome parameters, bcl-2 versus germlineImpact of additional genetic changes
CRPFSOS
United States113 NS NS6-150 NS Chromosome 17: decreased CR rate (P < .01)  
United States99 —  —  Lower  (P = .02) del17, dup2: trend to worse outcome 
    dup3 or + 3: trend to better outcome 
Denmark93 —  —  NS —  
France114 —  —  NS Abnormal CG: worse outcome, including: 1p21-22 (P < .01), 6q23-6 (P < .001), 17p (P < .001), no. chromosome breaks > 6 (P < .01) 
Sweden89 —  —  Higher  (P = .011) —  
United States132 —  —  NS Bcl-611 patients (9 of whom + bcl-2): OS better thanbcl-6 germline  
United States83 Lower Lower NS —  
Canada97 —  NS  NS Increased rate trisomy3 in bcl-2 −ve (P < .01), trend del10q in bcl-2 +ve (P = .08)  
United States96 —  —  NS 17p reduced 5-year OS (P = .058), + 21 (P = .013) reduced 5-year OS  
United States115 —  —  NS Any of + 7/+ 12/1p: decreased median survival (P = .028) 
CountryOutcome parameters, bcl-2 versus germlineImpact of additional genetic changes
CRPFSOS
United States113 NS NS6-150 NS Chromosome 17: decreased CR rate (P < .01)  
United States99 —  —  Lower  (P = .02) del17, dup2: trend to worse outcome 
    dup3 or + 3: trend to better outcome 
Denmark93 —  —  NS —  
France114 —  —  NS Abnormal CG: worse outcome, including: 1p21-22 (P < .01), 6q23-6 (P < .001), 17p (P < .001), no. chromosome breaks > 6 (P < .01) 
Sweden89 —  —  Higher  (P = .011) —  
United States132 —  —  NS Bcl-611 patients (9 of whom + bcl-2): OS better thanbcl-6 germline  
United States83 Lower Lower NS —  
Canada97 —  NS  NS Increased rate trisomy3 in bcl-2 −ve (P < .01), trend del10q in bcl-2 +ve (P = .08)  
United States96 —  —  NS 17p reduced 5-year OS (P = .058), + 21 (P = .013) reduced 5-year OS  
United States115 —  —  NS Any of + 7/+ 12/1p: decreased median survival (P = .028) 

CR indicates complete remission; PFS, progression-free survival; and OS, overall survival.

F6-150

Failure-free survival.

Sehn et al97 from Vancouver analyzed the karyotype of tumor cells in their series of 212 patients with FL. They found patients with t(14;18) translocations to be more likely to have grade 1 histology with a higher likelihood of bone marrow involvement. Contrary to the findings of Lopez-Guillermo et al,83 they found a correlation between the bcl-2 translocation and advanced stage. There are potential discrepancies in results across these reports, which may partly be attributable to the small sample size of the earlier studies, lymphoma histologies included in each study, and differences in technical methods (cytogenetics vs PCR detection of translocations). Nonetheless, these observations are consistent with the proposal that the presence or absence ofbcl-2 gene rearrangements may be associated with distinct disease features and natural history.

As discussed above, molecular events subsequent to the acquisition of the t(14;18) translocation may be necessary and rate-limiting in the development of FL. Indeed, as with the presence or absence of thebcl-2 translocation, these secondary events may similarly be associated with distinct clinical characteristics and outcome parameters despite morphologic equivalence. Numerous nonrandom chromosomal abnormalities in FL are reported in the literature (summarized in Table 6).

Most FL, in addition to the characteristic t(14;18), demonstrate at least one additional karyotypic abnormality.98,99 Earlier work by Yunis et al100 not only demonstrated distinct patterns of these additional chromosomal changes for specific FL histologies, they also found that the number of accumulated additional abnormalities increased from indolent FSC histology to FLC and diffuse large-cell histology. For instance, they defined a group of patients with clinically aggressive FSC on the basis of chemoresistance and shortened survival in whom either loss of chromosome 13 or trisomy of chromosome 2 was consistently detected. In addition, if a large-cell component of FL was present (FMC and FLC), 6 nonrandom defects were common, including +21, which was exclusive to FLC. There is no direct evidence yet available in humans that molecular events accumulate over time to transform a bcl-2–harboring lymphoid cell into clinically evident FL. Indirect evidence that subsequent molecular events are required for disease progression includes the above differences in accumulated genetic mutations between the 3 FL subtypes and the observation that transformation to aggressive lymphoma is also accompanied by cumulative genetic changes.101-104 Specific molecular abnormalities of FL thus predict histologic transformation.

Chromosomal translocations involving the bcl-6 locus are another group of molecular events implicated as a putative mechanism of FL development. The bcl-6 gene on 3q27 generates the corresponding protein that specifically regulates B-cell progression and differentiation within the germinal center. It is postulated that, as a result of bcl-6 translocation, physiologicbcl-6 gene down-regulation following germinal center transition does not occur, preventing subsequent lymphocyte differentiation.105 It is one of the most common mutations in diffuse large B-cell lymphomas.106-109 In FL, abcl-6 translocation is also recognized, but at a much lower frequency.106,107,110 The presence of a bcl-6gene rearrangement in the absence of bcl-2 by cytogenetic analysis in a single patient with FL was reported in 1992.111 However, a more recent analysis of a series of 208 well-characterized FL revealed bcl-6 rearrangement by Southern blotting in the absence of t(14;18) of bcl-2rearrangement in 15 patients (7.2%). These bcl6+/bcl-2 patients infrequently expressed CD10 (28%) or bcl-2 protein (22%) by immunohistochemistry and appeared to have a similar natural history tobcl-2–rearranged FL.112 This establishes that dysregulation of bcl-6 occurs in a subset of bcl-2 germline FL patients and suggests that such dysregulation may be an initiating event in FL, though these cases were not studied for other putative initiating molecular events. The role of bcl-6 dysregulation in the pathogenesis of FL warrants further investigation.

Additional specific chromosomal changes, most commonly involving chromosome 17, did predict for an inferior outcome in the report of Levine et al.113 Similarly, Tilly et al114correlated adverse outcomes with the presence of chromosome 17 and 1p and 6q abnormalities. Offit et al115 reported reduced overall survival in FL patients with cytogenetic abnormalities at 1p or with trisomy of chromosome 12 or 7. None of these reports analyzed prognosis by subtype of FL. Of great interest, Sehn et al97 also found differences in the frequency of cytogenetic abnormalities between bcl-2translocation-positive and translocation-negative patients. This observation lends further support to the 2-pathway model.

The cited results from Sehn et al97 warrant further comment. The lower t(14;18) translocation rate in Asian populations would not of itself be sufficient to explain the reduced absolute incidence rates of FL; there must also be a lower absolute incidence rate of bcl-2 germline FL cases. If the reduction is proportional between bcl-2–rearranged and germline cases, it would be consistent with the hypothesis that there were shared “subsequent” events leading to clinical follicular lymphoma in both groups. However, the differences in cytogenetic characteristic abnormalities between the 2 groups, as reported by Sehn et al, are inconsistent with this suggestion.

These secondary or alternative abnormalities, and not thebcl-2 gene rearrangement, may be the relevant independent indicator of clinical or outcome characteristics. Again, greater numbers of patients and prospectively collected data are required to identify these.

The relatively high rate of bcl-2 translocation in the absence of FL calls into question its use as an appropriate marker of molecular monitoring. Indeed, in localized FL, a detectablebcl-2 translocation can be found in the peripheral blood or bone marrow of some patients.90,116-118 Moreover, during long-term follow-up, some patients remain in complete remission despite ongoing bcl-2 positivity detectable by sensitive PCR assays.90,119,120 Nonetheless, recent data have demonstrated that the achievement of complete molecular remission (CMR) is associated with improved outcomes.121-123 Historically, the use of conventional alkylating agents or anthracycline-based chemotherapy does not produce CMR, even in patients with complete clinical response rates of more than 80%.57,87,124-126However, novel treatments that include fludarabine-based combination regimens and the monoclonal antibody rituximab have been associated with substantial CMR rates.121,123 Similarly, results of in vitro autologous stem cell purging to produce bcl-2 PCR negativity have also demonstrated encouraging results.127 128 Thus aggressive treatment strategies that maximize the CMR rate may improve clinical endpoints and change the treatment paradigm in advanced FL.

In the absence of available downstream molecular targets, the monitoring of minimal residual disease in FL is based on PCR-detectablebcl-2 gene rearrangement. Assuming that the putative downstream events discussed are rate-limiting and are required for progression to clinical disease, their elucidation may help to better define specific subcategories of FL with respect to clinical characteristics and outcomes. These secondary events may better reflect true minimal residual disease than the presence of PCR-detectablebcl-2 gene rearrangement alone, and their identification may provide clues to more effective therapeutic targets. Gene expression profiling by microarray techniques, a novel technology yet to enter clinical application, offers a potentially powerful method for the characterization of FL.129-131 

We have demonstrated, from analysis of the available published data, a significantly lower incidence of bcl-2 translocation in FL between Asian and Western countries, despite similar rates ofbcl-2 positivity in healthy persons for both population groups. This observation supports our hypothesis that molecular pathogenesis of FL may vary across geographic regions and, further, may explain the differences in the incidence rates commonly reported. If these findings were confirmed in prospective studies, it would imply that different etiologic or genetic factors may influence the development of FL across separate regions.

Portions of this paper were presented at the IX Congress of The International Society of Haematology, Asian-Pacific Division, Bangkok, October 1999, and were published in the corresponding Education Programme and Scientific Supplement.

1
Anonymous
National Cancer Institute-sponsored study of classifications of non-Hodgkin's lymphomas: summary and description of a working formulation for clinical usage. The Non-Hodgkin's Lymphoma Pathologic Classification Project.
Cancer.
49
1982
2112
2135
2
Anonymous
Statistical analyses of clinico-pathological, virological and epidemiological data on lymphoid malignancies with special reference to adult T-cell leukemia/lymphoma: a report of the second nationwide study of Japan: the T- and B-Cell Malignancy Study Group.
Jpn J Clin Oncol.
15
1985
517
535
3
Anderson
JR
Armitage
JO
Weisenburger
DD
Epidemiology of the non-Hodgkin's lymphomas: distributions of the major subtypes differ by geographic locations. Non-Hodgkin's Lymphoma Classification Project.
Ann Oncol.
9
1998
717
720
4
Calderon
B
Villalon
A
Augustin
B
Javier
B
Zamuco
J
Mori
S
Malignant lymphoma in Manila—a clinicopathologic study at the University of the Philippines-Philippine General Hospital Medical Center.
Jpn J Clin Oncol.
16
1986
21
27
5
Chi
JG
Shin
SS
Ahn
GH
Lee
SK
Malignant lymphomas in Korea.
Jpn J Clin Oncol.
15
1985
653
659
6
Garg
A
Dawar
R
Agarwal
V
Rustagi
RK
Kochupillai
V
Non-Hodgkin's lymphoma in northern India: a retrospective analysis of 238 cases.
Cancer.
56
1985
972
977
7
Harrington
DS
Ye
YL
Weisenburger
DD
et al
Malignant lymphoma in Nebraska and Guangzhou, China: a comparative study.
Hum Pathol.
18
1987
924
928
8
Ho
FC
Todd
D
Loke
SL
Ng
RP
Khoo
RK
Clinico-pathological features of malignant lymphomas in 294 Hong Kong Chinese patients: retrospective study covering an eight-year period.
Int J Cancer.
34
1984
143
148
9
Intragumtornchai
T
Wannakrairoj
P
Chaimongkol
B
et al
Non-Hodgkin's lymphomas in Thailand: a retrospective pathologic and clinical analysis of 1391 cases.
Cancer.
78
1996
1813
1819
10
Kadin
ME
Berard
CW
Nanba
K
Wakasa
H
Lymphoproliferative diseases in Japan and Western countries: Proceedings of the United States–Japan Seminar, September 6 and 7, 1982, in Seattle, Washington.
Hum Pathol.
14
1983
745
772
11
Kim
CW
Kim
I
Ko
YH
et al
Clinicopathologic and immunophenotypic study of non-Hodgkin's lymphoma in Korea: Lymphoreticular Study Group of the Korean Society of Pathologists.
J Korean Med Sci.
7
1992
193
198
12
Ko
YH
Kim
CW
Park
CS
et al
REAL classification of malignant lymphomas in the Republic of Korea: incidence of recently recognized entities and changes in clinicopathologic features: Hematolymphoreticular Study Group of the Korean Society of Pathologists: revised European-American lymphoma.
Cancer.
83
1998
806
812
13
Kushwaha
MR
Chandra
D
Misra
NC
Misra
PK
Agarwal
SS
Leukaemias and lymphomas at Lucknow, India.
Leuk Res.
9
1985
799
802
14
Shih
LY
Liang
DC
Non-Hodgkin's lymphomas in Asia.
Hematol Oncol Clin North Am.
5
1991
983
1001
15
Sukpanichnant
S
Sonakul
D
Piankijagum
A
et al
Malignant lymphoma in Thailand: changes in the frequency of malignant lymphoma determined from a histopathologic and immunophenotypic analysis of 425 cases at Siriraj Hospital.
Cancer.
83
1998
1197
1204
16
Bamanikar
S
Thunold
S
Devi
KR
Bamanikar
A
The pattern of malignant lymphoma in Oman.
J Trop Med Hyg.
98
1995
351
354
17
Ahmad
M
Khan
AH
Mansoor
A
Khan
MA
Saeed
S
Non-Hodgkin's lymphoma—clinicopathological pattern.
J Pak Med Assoc.
42
1992
205
207
18
Obafunwa
JO
Akinsete
I
Malignant lymphomas in Jos, Nigeria: a ten-year study.
Cent Afr J Med.
38
1992
17
25
19
Walter
PR
Klotz
F
Alfy-Gattas
T
Minko-Mi-Etoua
D
Nguembi-Mbina
C
Malignant lymphomas in Gabon (equatorial Africa): a morphologic study of 72 cases.
Hum Pathol.
22
1991
1040
1043
20
Herrinton
LJ
Goldoft
M
Schwartz
SM
Weiss
NS
The incidence of non-Hodgkin's lymphoma and its histologic subtypes in Asian migrants to the United States and their descendants.
Cancer Causes Control.
7
1996
224
230
21
Hakulinen
T
Methodological problems in comparing incidence and prevalence of leukaemias and lymphomas: ascertainment and age adjustment.
Leukemia.
13(suppl 1)
1999
S37
S41
22
Devesa
SS
Fears
T
Non-Hodgkin's lymphoma time trends: United States and international data.
Cancer Res.
52(suppl)
1992
5432
5440
23
Parkin
D
Whelan
S
Ferlay
J
Raymond
L
Young
J
Cancer incidence in five continents, volume VII. IARC Scientific Publication No. 143.
1997
24
Howe
HL
Wingo
PA
Thun
MJ
et al
Annual report to the nation on the status of cancer (1973 through 1998), featuring cancers with recent increasing trends.
J Natl Cancer Inst.
93
2001
824
842
25
Cartwright
R
Brincker
H
Carli
PM
et al
The rise in incidence of lymphomas in Europe 1985–1992.
Eur J Cancer.
35
1999
627
633
26
Holford
TR
Zheng
T
Mayne
ST
McKay
LA
Time trends of non-Hodgkin's lymphoma: are they real? what do they mean?
Cancer Res.
52(suppl)
1992
5443
5446
27
Groves
FD
Linet
MS
Travis
LB
Devesa
SS
Cancer surveillance series: non-Hodgkin's lymphoma incidence by histologic subtype in the United States from 1978 through 1995.
J Natl Cancer Inst.
92
2000
1240
1251
28
Harris
NL
Jaffe
ES
Diebold
J
et al
World Health Organization classification of neoplastic diseases of the hematopoietic and lymphoid tissues: report of the Clinical Advisory Committee Meeting: Airlie House, Virginia, November 1997.
J Clin Oncol.
17
1999
3835
3849
29
Mann
RB
Berard
CW
Criteria for the cytologic subclassification of follicular lymphomas: a proposed alternative method.
Hematol Oncol.
1
1983
187
192
30
Metter
GE
Nathwani
BN
Burke
JS
et al
Morphological subclassification of follicular lymphoma: variability of diagnoses among hematopathologists, a collaborative study between the Repository Center and Pathology Panel for Lymphoma Clinical Studies.
J Clin Oncol.
3
1985
25
38
31
Nathwani
BN
Metter
GE
Miller
TP
et al
What should be the morphologic criteria for the subdivision of follicular lymphomas?
Blood.
68
1986
837
845
32
Newton
R
Ferlay
J
Beral
V
Devesa
SS
The epidemiology of non-Hodgkin's lymphoma: comparison of nodal and extra-nodal sites.
Int J Cancer.
72
1997
923
930
33
Rabkin
CS
Devesa
SS
Zahm
SH
Gail
MH
Increasing incidence of non-Hodgkin's lymphoma.
Semin Hematol.
30
1993
286
296
34
Scherr
PA
Mueller
NE
Non-Hodgkin's lymphoma.
Cancer Epidemiology and Prevention.
Schottenfeld
D
Fraumeni
JF
1996
920
945
Oxford University Press
New York, NY
35
Korsmeyer
SJ
Bcl-2 initiates a new category of oncogenes: regulators of cell death.
Blood.
80
1992
879
886
36
Kroemer
G
The proto-oncogene Bcl-2 and its role in regulating apoptosis.
Nat Med.
3
1997
614
620
37
Yang
E
Korsmeyer
SJ
Molecular thanatopsis: a discourse on the BCL2 family and cell death.
Blood.
88
1996
386
401
38
Tsujimoto
Y
Finger
LR
Yunis
J
Nowell
PC
Croce
CM
Cloning of the chromosome breakpoint of neoplastic B cells with the t(14;18) chromosome translocation.
Science.
226
1984
1097
1099
39
Tsujimoto
Y
Croce
CM
Analysis of the structure, transcripts, and protein products of bcl-2, the gene involved in human follicular lymphoma.
Proc Natl Acad Sci U S A.
83
1986
5214
5218
40
Yunis
JJ
Oken
MM
Kaplan
ME
Ensrud
KM
Howe
RR
Theologides
A
Distinctive chromosomal abnormalities in histologic subtypes of non-Hodgkin's lymphoma.
N Engl J Med.
307
1982
1231
1236
41
Strasser
A
Harris
AW
Corcoran
LM
Cory
S
Bcl-2 expression promotes B- but not T-lymphoid development in SCID mice.
Nature.
368
1994
457
460
42
McDonnell
TJ
Deane
N
Platt
FM
et al
bcl-2-immunoglobulin transgenic mice demonstrate extended B cell survival and follicular lymphoproliferation.
Cell.
57
1989
79
88
43
Lee
MS
Chang
KS
Cabanillas
F
Freireich
EJ
Trujillo
JM
Stass
SA
Detection of minimal residual cells carrying the t(14;18) by DNA sequence amplification.
Science.
237
1987
175
178
44
Wang
YL
Addya
K
Edwards
RH
et al
Novel bcl-2 breakpoints in patients with follicular lymphoma.
Diagn Mol Pathol.
7
1998
85
89
45
Buchonnet
G
Lenain
P
Ruminy
P
et al
Characterisation of BCL2-JH rearrangements in follicular lymphoma: PCR detection of 3' BCL2 breakpoints and evidence of a new cluster.
Leukemia.
14
2000
1563
1569
46
Horsman
DE
Gascoyne
RD
Coupland
RW
Coldman
AJ
Adomat
SA
Comparison of cytogenetic analysis, Southern analysis, and polymerase chain reaction for the detection of t(14; 18) in follicular lymphoma.
Am J Clin Pathol.
103
1995
472
478
47
Séité
P
Hillion
J
D'Agay
MF
et al
BCL2 gene activation and protein expression in follicular lymphoma: a report on 64 cases.
Leukemia.
7
1993
410
417
48
Papakonstantinou
G
Verbeke
C
Hastka
J
Bohrer
M
Hehlmann
R
bcl-2 expression in non-Hodgkin's lymphomas is not associated with bcl- 2 gene rearrangements .
Br J Haematol.
113
2001
383
390
49
Pezzella
F
Gatter
KC
Mason
DY
et al
Bcl-2 protein expression in follicular lymphomas in absence of 14;18 translocation.
Lancet.
336
1990
1510
1511
50
Ngan
BY
Chen-Levy
Z
Weiss
LM
Warnke
RA
Cleary
ML
Expression in non-Hodgkin's lymphoma of the bcl-2 protein associated with the t(14;18) chromosomal translocation.
N Engl J Med.
318
1988
1638
1644
51
Lai
R
Arber
DA
Chang
KL
Wilson
CS
Weiss
LM
Frequency of bcl-2 expression in non-Hodgkin's lymphoma: a study of 778 cases with comparison of marginal zone lymphoma and monocytoid B-cell hyperplasia.
Mod Pathol.
11
1998
864
869
52
Limpens
J
de Jong
D
van Krieken
JH
et al
Bcl-2/JH rearrangements in benign lymphoid tissues with follicular hyperplasia.
Oncogene.
6
1991
2271
2276
53
Aster
JC
Kobayashi
Y
Shiota
M
Mori
S
Sklar
J
Detection of the t(14;18) at similar frequencies in hyperplastic lymphoid tissues from American and Japanese patients.
Am J Pathol.
141
1992
291
299
54
Bell
DA
Liu
Y
Cortopassi
GA
Occurrence of bcl-2 oncogene translocation with increased frequency in the peripheral blood of heavy smokers.
J Natl Cancer Inst.
87
1995
223
224
55
Dolken
G
Illerhaus
G
Hirt
C
Mertelsmann
R
BCL-2/JH rearrangements in circulating B cells of healthy blood donors and patients with nonmalignant diseases.
J Clin Oncol.
14
1996
1333
1344
56
Fuscoe
JC
Setzer
RW
Collard
DD
Moore
MM
Quantification of t(14;18) in the lymphocytes of healthy adult humans as a possible biomarker for environmental exposures to carcinogens.
Carcinogenesis.
17
1996
1013
1020
57
Ji
W
Qu
GZ
Ye
P
Zhang
XY
Halabi
S
Ehrlich
M
Frequent detection of bcl-2/JH translocations in human blood and organ samples by a quantitative polymerase chain reaction assay.
Cancer Res.
55
1995
2876
2882
58
Limpens
J
Stad
R
Vos
C
et al
Lymphoma-associated translocation t(14;18) in blood B cells of normal individuals.
Blood.
85
1995
2528
2536
59
Liu
Y
Hernandez
AM
Shibata
D
Cortopassi
GA
BCL2 translocation frequency rises with age in humans.
Proc Natl Acad Sci U S A.
91
1994
8910
8914
60
Ohshima
K
Kikuchi
M
Kobari
S
Masuda
Y
Eguchi
F
Kimura
N
Amplified bcl-2/JH rearrangements in reactive lymphadenopathy.
Virchows Arch B Cell Pathol Incl Mol Pathol.
63
1993
197
198
61
Rauzy
O
Galoin
S
Chale
JJ
et al
Detection of t(14;18) carrying cells in bone marrow and peripheral blood from patients affected by non-lymphoid diseases.
Mol Pathol.
51
1998
333
338
62
Summers
KE
Goff
LK
Wilson
AG
Gupta
RK
Lister
TA
Fitzgibbon
J
Frequency of the Bcl-2/IgH rearrangement in normal individuals: implications for the monitoring of disease in patients with follicular lymphoma.
J Clin Oncol.
19
2001
420
424
63
Delage
R
Roy
J
Jacques
L
Bernier
V
Delage
JM
Darveau
A
Multiple bcl-2/Ig gene rearrangements in persistent polyclonal B-cell lymphocytosis.
Br J Haematol.
97
1997
589
595
64
Paltiel
OB
Reches
A
Sverdlin
I
Zelenetz
AD
Yehuda
DB
The frequency of translocation t(14;18) in the peripheral blood of healthy individuals [abstract].
Blood.
98(suppl 1 part 2)
2001
154
65
Yasukawa
M
Bando
S
Dolken
G
et al
Low frequency of BCL-2/J(H) translocation in peripheral blood lymphocytes of healthy Japanese individuals.
Blood.
98
2001
486
488
66
Poetsch
M
Weber-Matthiesen
K
Plendl
HJ
Grote
W
Schlegelberger
B
Detection of the t(14;18) chromosomal translocation by interphase cytogenetics with yeast-artificial-chromosome probes in follicular lymphoma and nonneoplastic lymphoproliferation.
J Clin Oncol.
14
1996
963
969
67
Cleary
ML
Sklar
J
Nucleotide sequence of a t(14;18) chromosomal breakpoint in follicular lymphoma and demonstration of a breakpoint-cluster region near a transcriptionally active locus on chromosome 18.
Proc Natl Acad Sci U S A.
82
1985
7439
7443
68
Bakhshi
A
Jensen
JP
Goldman
P
et al
Cloning the chromosomal breakpoint of t(14;18) human lymphomas: clustering around JH on chromosome 14 and near a transcriptional unit on 18.
Cell.
41
1985
899
906
69
Tsujimoto
Y
Gorham
J
Cossman
J
Jaffe
E
Croce
CM
The t(14;18) chromosome translocations involved in B-cell neoplasms result from mistakes in VDJ joining.
Science.
229
1985
1390
1393
70
Price
CG
Tuszynski
A
Watt
SM
Murdoch
SJ
Lister
TA
Young
BD
Detection of additional JH/BCL2 translocations in follicular lymphoma.
Leukemia.
5
1991
548
554
71
Louie
DC
Kant
JA
Brooks
JJ
Reed
JC
Absence of t(14;18) major and minor breakpoints and of Bcl-2 protein overproduction in Reed-Sternberg cells of Hodgkin's disease.
Am J Pathol.
139
1991
1231
1237
72
Cotter
F
Price
C
Zucca
E
Young
BD
Direct sequence analysis of the 14q+ and 18q− chromosome junctions in follicular lymphoma.
Blood.
76
1990
131
135
73
Gauwerky
CE
Hoxie
J
Nowell
PC
Croce
CM
Pre-B-cell leukemia with a t(8;14) and a t(14;18) translocation is preceded by follicular lymphoma.
Oncogene.
2
1988
431
435
74
Seto
M
Osada
H
Ueda
R
et al
bcl-2 translocation in Japanese B cell lymphoma: novel bcl-2 translocation with immunoglobulin heavy-chain diversity segment.
Jpn J Cancer Res.
82
1991
65
71
75
Soubeyran
P
Hostein
I
Debled
M
et al
Evolution of BCL-2/IgH hybrid gene RNA expression during treatment of T(14;18)-bearing follicular lymphomas.
Br J Cancer.
81
1999
860
869
76
Franceschi
S
Serraino
D
Bidoli
E
et al
The epidemiology of non-Hodgkin's lymphoma in the northeast of Italy: a hospital-based case-control study.
Leuk Res.
13
1989
465
472
77
Brown
LM
Everett
GD
Gibson
R
Burmeister
LF
Schuman
LM
Blair
A
Smoking and risk of non-Hodgkin's lymphoma and multiple myeloma.
Cancer Causes Control.
3
1992
49
55
78
Linet
MS
McLaughlin
JK
Hsing
AW
et al
Is cigarette smoking a risk factor for non-Hodgkin's lymphoma or multiple myeloma? results from the Lutheran Brotherhood Cohort Study.
Leuk Res.
16
1992
621
624
79
Zahm
SH
Weisenburger
DD
Holmes
FF
Cantor
KP
Blair
A
Tobacco and non-Hodgkin's lymphoma: combined analysis of three case-control studies (United States).
Cancer Causes Control.
8
1986
651
656
80
Herrinton
LJ
Friedman
GD
Cigarette smoking and risk of non-Hodgkin's lymphoma subtypes.
Cancer Epidemiol Biomarkers Prev.
7
1998
25
28
81
Nelson
RA
Levine
AM
Marks
G
Bernstein
L
Alcohol, tobacco and recreational drug use and the risk of non-Hodgkin's lymphoma.
Br J Cancer.
76
1997
1532
1537
82
Segel
MJ
Paltiel
O
Zimran
A
et al
Geographic variance in the frequency of the t(14;18) translocation in follicular lymphoma: an Israeli series compared to the world.
Blood Cells Mol Dis.
24
1998
62
72
83
Lopez-Guillermo
A
Cabanillas
F
McDonnell
TI
et al
Correlation of bcl-2 rearrangement with clinical characteristics and outcome in indolent follicular lymphoma.
Blood.
93
1999
3081
3087
84
Liu
J
Johnson
RM
Traweek
ST
Rearrangement of the BCL-2 gene in follicular lymphoma: detection by PCR in both fresh and fixed tissue samples.
Diagn Mol Pathol.
2
1993
241
247
85
Loke
SL
Pittaluga
S
Srivastava
G
Raffeld
M
Ho
FC
Translocation of bcl-2 gene in non-Hodgkin's lymphomas in Hong Kong Chinese.
Br J Haematol.
76
1990
65
69
86
Benitez
J
Robledo
M
Santon
A
et al
Correlation between cytogenetic and molecular analysis of t(14;18) in follicular lymphomas.
Cancer Genet Cytogenet.
59
1992
68
72
87
Gribben
JG
Freedman
A
Woo
SD
et al
All advanced stage non-Hodgkin's lymphomas with a polymerase chain reaction amplifiable breakpoint of bcl-2 have residual cells containing the bcl-2 rearrangement at evaluation and after treatment.
Blood.
78
1991
3275
3280
88
Gulley
ML
Dent
GA
Ross
DW
Classification and staging of lymphoma by molecular genetics.
Cancer.
69
1992
1600
1606
89
Johnson
A
Brun
A
Dictor
M
Rambech
E
Akerman
M
Anderson
H
Incidence and prognostic significance of t(14;18) translocation in follicle center cell lymphoma of low and high grade: a report from southern Sweden.
Ann Oncol.
6
1995
789
794
90
Lambrechts
AC
Hupkes
PE
Dorssers
LC
van't Veer
MB
Translocation (14;18)-positive cells are present in the circulation of the majority of patients with localized (stage I and II) follicular non- Hodgkin's lymphoma.
Blood.
82
1993
2510
2516
91
Lee
KA
Goepel
JR
Winfield
DA
Hancock
BW
Goyns
MH
Investigation of BCL-2 gene rearrangements in a United Kingdom series of low and high grade non-Hodgkin's lymphomas.
Leuk Lymphoma.
11
1993
91
98
92
Mitani
S
Aoki
N
Mizutani
S
et al
bcl-2 gene rearrangement analysis of Japanese follicular lymphomas by polymerase chain reaction in formalin-fixed, paraffin-embedded tissue specimens.
Jpn J Cancer Res.
84
1993
37
41
93
Pezzella
F
Ralfkiaer
E
Gatter
KC
Mason
DY
The 14;18 translocation in European cases of follicular lymphoma: comparison of Southern blotting and the polymerase chain reaction.
Br J Haematol.
76
1990
58
64
94
Zelenetz
AD
Chu
G
Galili
N
et al
Enhanced detection of the t(14;18) translocation in malignant lymphoma using pulsed-field gel electrophoresis.
Blood.
78
1991
1552
1560
95
Starostik
P
Patzner
J
Greiner
A
et al
Gastric marginal zone B-cell lymphomas of MALT type develop along 2 distinct pathogenetic pathways.
Blood.
99
2002
3
9
96
Weisenburger
DD
Gascoyne
RD
Bierman
PJ
et al
Clinical significance of the t(14;18) and BCL2 overexpression in follicular large cell lymphoma.
Leuk Lymphoma.
36
2000
513
523
97
Sehn
LH
Gascoyne
RD
Connors
JM
Klasa
RJ
Horsman
DE
Comparison of t(14;18) positive and t(14;18) negative follicular lymphoma (FL): clinical characteristics, outcomes and cytogenetics [abstract].
Blood.
96(suppl 1)
2000
574
98
Bloomfield
CD
Arthur
DC
Frizzera
G
Levine
EG
Peterson
BA
Gajl-Peczalska
KJ
Nonrandom chromosome abnormalities in lymphoma.
Cancer Res.
43
1983
2975
2984
99
Yunis
JJ
Mayer
MG
Arnesen
MA
Aeppli
DP
Oken
MM
Frizzera
G
bcl-2 and other genomic alterations in the prognosis of large-cell lymphoma.
N Engl J Med.
320
1989
1047
1054
100
Yunis
JJ
Frizzera
G
Oken
MM
McKenna
J
Theologides
A
Arnesen
M
Multiple recurrent genomic defects in follicular lymphoma: a possible model for cancer.
N Engl J Med.
316
1987
79
84
101
Salles
G
Coiffier
B
Histologic transformation in follicular lymphoma.
Ann Oncol.
9
1998
803
805
102
Yano
T
Jaffe
ES
Longo
DL
Raffeld
M
MYC rearrangements in histologically progressed follicular lymphomas.
Blood.
80
1992
758
767
103
Pinyol
M
Cobo
F
Bea
S
et al
p16(INK4a) gene inactivation by deletions, mutations, and hypermethylation is associated with transformed and aggressive variants of non-Hodgkin's lymphomas.
Blood.
91
1998
2977
2984
104
Sander
CA
Yano
T
Clark
HM
et al
p53 mutation is associated with progression in follicular lymphomas.
Blood.
82
1993
1994
2004
105
Ye
BH
Lista
F
Lo
CF
et al
Alterations of a zinc finger-encoding gene, BCL-6, in diffuse large- cell lymphoma.
Science.
262
1993
747
750
106
Bastard
C
Deweindt
C
Kerckaert
JP
et al
LAZ3 rearrangements in non-Hodgkin's lymphoma: correlation with histology, immunophenotype, karyotype, and clinical outcome in 217 patients.
Blood.
83
1994
2423
2427
107
Butler
M
Corbally
N
Dervan
PA
Carney
DN
BCL-6 and other genomic alterations in non-Hodgkin's lymphoma (NHL).
Br J Cancer.
75
1997
1641
1645
108
Offit
K
Lo
CF
Louie
DC
et al
Rearrangement of the bcl-6 gene as a prognostic marker in diffuse large-cell lymphoma.
N Engl J Med.
331
1994
74
80
109
Lo
CF
Ye
BH
Lista
F
et al
Rearrangements of the BCL6 gene in diffuse large cell non-Hodgkin's lymphoma.
Blood.
83
1994
1757
1759
110
Offit
K
Jhanwar
S
Ebrahim
SA
Filippa
D
Clarkson
BD
Chaganti
RS
t(3;22)(q27;q11): a novel translocation associated with diffuse non-Hodgkin's lymphoma.
Blood.
74
1989
1876
1879
111
Bastard
C
Tilly
H
Lenormand
B
et al
Translocations involving band 3q27 and Ig gene regions in non-Hodgkin's lymphoma.
Blood.
79
1992
2527
2531
112
Jardin
F
Buchonnet
G
Contentin
N
et al
Follicular lymphoma (FL) with BCL6 rearrangement: a lymphoma subtype with distinct pathological, molecular and clinical characteristics [abstract].
Blood.
98(suppl 1)
2001
723
113
Levine
EG
Arthur
DC
Frizzera
G
Peterson
BA
Hurd
DD
Bloomfield
CD
Cytogenetic abnormalities predict clinical outcome in non-Hodgkin lymphoma.
Ann Intern Med.
108
1988
14
20
114
Tilly
H
Rossi
A
Stamatoullas
A
et al
Prognostic value of chromosomal abnormalities in follicular lymphoma.
Blood.
84
1994
1043
1049
115
Offit
K
Jhanwar
SC
Ladanyi
M
Filippa
DA
Chaganti
RS
Cytogenetic analysis of 434 consecutively ascertained specimens of non- Hodgkin's lymphoma: correlations between recurrent aberrations, histology, and exposure to cytotoxic treatment.
Genes Chromosomes Cancer.
3
1991
189
201
116
Ha
CS
Cabanillas
F
Lee
MS
Besa
PC
McLaughlin
P
Cox
JD
Serial determination of the bcl-2 gene in the bone marrow and peripheral blood after central lymphatic irradiation for stages I-III follicular lymphoma: a preliminary report.
Clin Cancer Res.
3
1997
215
219
117
Berinstein
NL
Jamal
HH
Kuzniar
B
Klock
RJ
Reis
MD
Sensitive and reproducible detection of occult disease in patients with follicular lymphoma by PCR amplification of t(14;18) both pre- and post-treatment.
Leukemia.
7
1993
113
119
118
Berinstein
NL
Reis
MD
Ngan
BY
Sawka
CA
Jamal
HH
Kuzniar
B
Detection of occult lymphoma in the peripheral blood and bone marrow of patients with untreated early-stage and advanced-stage follicular lymphoma.
J Clin Oncol.
11
1993
1344
1352
119
Finke
J
Slanina
J
Lange
W
Dolken
G
Persistence of circulating t(14;18)-positive cells in long-term remission after radiation therapy for localized-stage follicular lymphoma.
J Clin Oncol.
11
1993
1668
1673
120
Price
CG
Meerabux
J
Murtagh
S
et al
The significance of circulating cells carrying t(14;18) in long remission from follicular lymphoma.
J Clin Oncol.
9
1991
1527
1532
121
Lopez-Guillermo
A
Cabanillas
F
McLaughlin
P
et al
The clinical significance of molecular response in indolent follicular lymphomas.
Blood.
91
1998
2955
2960
122
Lopez-Guillermo
A
Cabanillas
F
McLaughlin
P
et al
Molecular response assessed by PCR is the most important factor predicting failure-free survival in indolent follicular lymphoma: update of the MDACC series.
Ann Oncol.
11(suppl 1)
2000
137
140
123
Colombat
P
Salles
G
Brousse
N
et al
Rituximab (anti-CD20 monoclonal antibody) as single first-line therapy for patients with follicular lymphoma with a low tumor burden: clinical and molecular evaluation.
Blood.
97
2001
101
106
124
Bertoni
F
Bosshard
G
Roggero
E
Ceresa
E
Cavalli
F
Zucca
E
Clinical relevance of bcl-2(MBR)/J(H) rearrangement detected by polymerase chain reaction in the peripheral blood of patients with follicular lymphoma.
Br J Cancer.
76
1997
36
39
125
Lambrechts
AC
Hupkes
PE
Dorssers
LC
van't Veer
MB
Clinical significance of t(14; 18)-positive cells in the circulation of patients with stage III or IV follicular non-Hodgkin's lymphoma during first remission.
J Clin Oncol.
12
1994
1541
1546
126
Moos
M
Schulz
R
Martin
S
Benner
A
Haas
R
The remission status before and the PCR status after high-dose therapy with peripheral blood stem cell support are prognostic factors for relapse-free survival in patients with follicular non-Hodgkin's lymphoma.
Leukemia.
12
1998
1971
1976
127
Colombat
P
Cornillet
P
Deconinck
E
et al
Value of autologous stem cell transplantation with purged bone marrow as first-line therapy for follicular lymphoma with high tumor burden: a GOELAMS phase II study.
Bone Marrow Transplant.
26
2000
971
977
128
Gonzalez-Barca
E
Fernandez
DS
Domingo-Claros
A
et al
Autologous stem cell transplantation (ASCT) with immunologically purged progenitor cells in patients with advanced stage follicular lymphoma after early partial or complete remission: toxicity, follow-up of minimal residual disease and survival.
Bone Marrow Transplant.
26
2000
1051
1056
129
Alizadeh
AA
Eisen
MB
Davis
RE
et al
Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling.
Nature.
403
2000
503
511
130
Dales
JP
Plumas
J
Palmerini
F
et al
Correlation between apoptosis microarray gene expression profiling and histopathological lymph node lesions.
Mol Pathol.
54
2001
17
23
131
Husson
H
Carideo
EG
Neuberg
D
et al
Gene expression profiling of follicular lymphoma and normal germinal center B cells using cDNA arrays.
Blood.
99
2002
282
289
132
Louie
DC
Hochauser
D
Schluger
A
et al
BCL6 and BCL2 rearrangement and p53 overexpression as prognostic factors in follicular lymphoma [abstract].
Ann Oncol.
7
1996
16
133
Albinger-Hegyi
A
Hochreutener
B
Abdou
MT
et al
High frequency of t(14;18)-translocation breakpoints outside of major breakpoint and minor cluster regions in follicular lymphomas: improved polymerase chain reaction protocols for their detection.
Am J Pathol.
160
2002
823
832

Albinger-Hegyi et al133 sought the presence ofbcl-2 gene rearrangements in a series of 59 Swiss patients with FL. They found 32% (19) of cases to have MBR, and 3% (2) to have an mcr rearrangement that is broadly consistent with the previously published European frequencies. They then sequenced the entire 25-kb stretch of genomic DNA between the MBR and mcr regions, and designed novel PCR primers applicable to formalin-fixed tissue to allow detection of breakpoints in this intervening period. Using these novel methods, they identified an additional 36% (21) of cases with otherwise undetected bcl-2 rearrangements. Importantly 12% (7) of their total sample had breakpoints clustered in an approximately 200-bp region they have called the intermediate cluster region (icr). The geographic variation in frequency of icr breakpoints in FL remains to be explored.

Author notes

John F. Seymour, Leukaemia/Lymphoma Service, The Department of Haematology, The Peter MacCallum Cancer Institute, Locked Bag 1, A'Beckett St, VIC 8006, Australia; e-mail:jseymour@petermac.unimelb.edu.au.

Sign in via your Institution